Bio-Techne stock jumps, with Germany’s Merck KGaA buying the company at a 24% premium.

Germany’s Merck KGaA will buy Bio-Techne Corp. in a deal worth $11.3 billion, one of the largest acquisitions in Minnesota ...

The transaction is a big splash for Merck KGaA, representing the company’s largest deal since its buyout of Sigma-Aldrich for ...

A German company that provides products and services that accelerate drug development and manufacturing is set to acquire the ...

The proposed acquisition will be the company’s biggest deal in more than a decade and represents an early move by new CEO Kai ...

Merck KGaA, Darmstadt, Germany, a leading science and technology company, and Bio-Techne Corporation, a Minneapolis-based ...

Bio-Techne Corp, has agreed to an acquisition offer by Germany’s Merck KGaA for about $11.3 billion, the largest M&A deal ...

By Padmanabhan Ananthan and Christy Santhosh June 25 (Reuters) - German drugmaker Merck KGaA said on Thursday it will acquire U.S. biotech firm Bio-Techne Corp for $11.3 billion, its largest deal in ...

Merck KGaA has agreed to acquire Bio-Techne (NasdaqGS:TECH) for $11.5b in an all cash deal. Bio-Techne's board has ...

On June 25, 2026, investors tracked deal progress as Bio-Techne shares responded to the proposed buyout terms.

Activist investor Ananym Capital Management has built a stake in Bio-Techne Corp. and is pushing the board to conduct a strategic review that would include a potential sale.

Q1 beat and Bio-Techne deal drive upside, but valuation looks full. Read here for a detailed investment analysis.